Tilray’s stock experienced a significant pullback on Wednesday, declining 4.6% to $1.66 with a downward gap opening. This retreat comes just days after the cannabis company’s shares had surged dramatically in response to former President Donald Trump’s endorsement of CBD products.
Market Reality Sets In After Initial Euphoria
The previous Monday had seen Tilray shares explode with a remarkable 60.87% gain after Trump used his Truth Social platform to promote CBD as revolutionary for senior health. The former president characterized hemp-based CBD as a viable alternative to prescription medications—a declaration that sent shockwaves through the entire cannabis sector.
However, this market enthusiasm proved short-lived as profit-taking emerged among investors. Wednesday’s downward gap indicates substantial institutional selling pressure, with trading volume exceeding 160 million shares—more than double the 65-day average of 66.31 million shares.
Earnings Report Looms
The heightened volatility coincides with the approaching earnings release scheduled for October 9 at 8:30 AM Eastern Time. Tilray will disclose its first-quarter financial results for fiscal year 2026 during this event.
Market experts have established the following expectations:
– Loss per share: -$0.03 (representing a 25% improvement year-over-year)
– Revenue: $206.83 million (a 3.39% increase compared to the same period last year)
– Annual revenue forecast: $877.28 million (projecting 6.81% growth)
Should investors sell immediately? Or is it worth buying Tilray?
European Expansion Progresses
Just one day before the stock’s decline, Tilray had announced positive developments in the German market. The company is expanding its premium cannabis production capabilities at its EU-GMP certified facility in Neumünster. Under Germany’s BfArM cultivation program, five new cannabis flower products will join the Tilray Craft portfolio.
This European expansion underscores Tilray’s strategic focus on international medical cannabis markets, where regulatory frameworks tend to be more stable than the evolving landscape in the United States.
Political Uncertainty Continues to Drive Volatility
Despite recent weakness, Tilray shares maintain a 34.06% monthly gain. However, Monday’s 52-week high of $1.86 has already been erased as the stock retreated.
The cannabis industry remains heavily influenced by political developments. Trump’s CBD comments initially fueled speculation about potential federal reclassification of cannabis, though concrete policy changes have yet to materialize. Institutional skepticism persists, reflected in a short interest representing 14.06% of tradable shares.
Tilray’s path to sustained profitability remains challenging, with significant cash burn and potential dilution risks continuing to cloud the company’s long-term outlook.
Ad
Tilray Stock: Buy or Sell?! New Tilray Analysis from February 7 delivers the answer:
The latest Tilray figures speak for themselves: Urgent action needed for Tilray investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.
Tilray: Buy or sell? Read more here...
